Child's Nervous System

, Volume 27, Issue 1, pp 55–62 | Cite as

The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis

  • Tao Jiang
  • Ge Jia
  • ZhenYu Ma
  • ShiQi Luo
  • YuQi Zhang
Original Paper

Abstract

Background

Subependymal giant cell astrocytoma develops in a small proportion of tuberous sclerosis patients. There are still several controversies on the early diagnosis of the tumor, treatment of hydrocephalus, and timing of operation, etc.

Methods

From September 1996 to April 2006, 17 patients were admitted in neurosurgical department of “Beijing Tiantan Hospital”. The authors analyzed medical records and followed up every case.

Results

There are 18 tumors out of 17 patients. One patient had double tumors. Sixteen patients except one underwent tumor resection 17 times. Fifteen tumors out of 17 were gross totally removed; two were partially removed. One patient died of brain infarction postoperatively. Three out of 13 patients with preoperative hydrocephalus still needed ventriculoperitoneal shunt after tumor resection. There was no recurrence after total resection.

Conclusion

Diagnosis of tumor should be made by clinical criteria. Serial follow-up is essential for a suspected perimonro lesion to find tumor growth earlier. When there is growth, tumor should be removed as soon as possible. Hydrocephalus will resolve in most cases after tumor resection, while external drainage is suitable for emergent cases. Transcallosal and transcortical approaches are both effective to resect the tumor. Tumor will not recur after total removal.

Keywords

Subependymal giant cell astrocytoma Tuberous sclerosis Surgical treatment Diagnosis 

References

  1. 1.
    Jansen FE, van Nieuwenhuizen O, van Huffelen AC (2004) Tuberous sclerosis complex and its founders. J Neurol Neurosurg Psychiatry 75:770CrossRefPubMedGoogle Scholar
  2. 2.
    Altman NR, Purser RK, Post MJ (1988) Tuberous sclerosis: characteristics at CT and MR imaging. Radiology 167:527–532PubMedGoogle Scholar
  3. 3.
    Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL (2003) Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 19:232–243PubMedGoogle Scholar
  4. 4.
    Goh S, Butler W, Thiele EA (2004) Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63:1457–1461PubMedGoogle Scholar
  5. 5.
    Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457–1466CrossRefPubMedGoogle Scholar
  6. 6.
    Curatolo P, Bombardieri R, Cerminara C (2006) Current management for epilepsy in tuberous sclerosis complex. Curr Opin Neuro l19:119–123CrossRefGoogle Scholar
  7. 7.
    de Ribaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard JM, Chiron C, Delalande O (2007) Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery 60:83–89PubMedGoogle Scholar
  8. 8.
    Dashti SR, Robinson S, Rodgers M, Cohen AR (2005) Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report. J Neurosurg 102(Suppl):322–325PubMedGoogle Scholar
  9. 9.
    Nagib MG, Haines SJ, Erickson DL, Mastri AR (1984) Tuberous sclerosis: a review for the neurosurgeon. Neurosurgery 14:93–98CrossRefPubMedGoogle Scholar
  10. 10.
    Conzen M, Oppel F (1990) Tuberous sclerosis in neurosurgery. An analysis of 18 patients. Acta Neurochir (Wien) 106:106–109CrossRefGoogle Scholar
  11. 11.
    Roach ES, DiMario FJ, Kandt RS, Northrup H (1999) Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 14:401–407CrossRefPubMedGoogle Scholar
  12. 12.
    Braffman BH, Bilaniuk LT, Naidich TP, Altman NR, Post MJ, Quencer RM, Zimmerman RA, Brody BA (1992) MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology 183:227–238PubMedGoogle Scholar
  13. 13.
    Nabbout R, Santos M, Rolland Y, Delalande O, Dulac O, Chiron C (1999) Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 66:370–375CrossRefPubMedGoogle Scholar
  14. 14.
    Bonnin JM, Rubinstein LJ, Papasozomenos SC, Marangos PJ (1984) Subependymal giant cell astrocytoma. Significance and possible cytogenetic implications of an immunohistochemical study. Acta Neuropathol 62:185–193CrossRefPubMedGoogle Scholar
  15. 15.
    Di Rocco C, Iannelli A, Marchese E (1995) On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg 23:115–121CrossRefPubMedGoogle Scholar
  16. 16.
    Turgut M, Akalan N, Ozgen T, Ruacan S, Erbengi A (1996) Subependymal giant cell astrocytoma associated with tuberous sclerosis: diagnostic and surgical characteristics of five cases with unusual features. Clin Neurol Neurosurg 98:217–221CrossRefPubMedGoogle Scholar
  17. 17.
    Shepherd CW, Gomez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66(8):792–796PubMedGoogle Scholar
  18. 18.
    Shepherd CW, Gomez MR (1991) Mortality in the Mayo Clinic Tuberous Sclerosis Complex Study. Ann N Y Acad Sci 615:375–377CrossRefPubMedGoogle Scholar
  19. 19.
    Prahlow JA, Teot LA, Lantz PE, Stanton CA (1995) Sudden death in epilepsy due to an isolated subependymal giant cell astrocytoma of the septum pellucidum. Am J Forensic Med Pathol 16:30–37CrossRefPubMedGoogle Scholar
  20. 20.
    Fujiwara S, Takaki T, Hikita T, Nishio S (1989) Subependymal giant-cell astrocytoma associated with tuberous sclerosis. Do subependymal nodules grow? Childs Nerv Syst 5:43–44CrossRefPubMedGoogle Scholar
  21. 21.
    Byard RW, Blumbergs PC, James RA (2003) Mechanisms of unexpected death in tuberous sclerosis. J Forensic Sci 48:172–176PubMedGoogle Scholar
  22. 22.
    Sinson G, Sutton LN, Yachnis AT, Duhaime AC, Schut L (1994) Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 20:233–239CrossRefPubMedGoogle Scholar
  23. 23.
    Kumar R, Singh V (2004) Subependymal giant cell astrocytoma: a report of five cases. Neurosurg Rev 27:274–280PubMedGoogle Scholar
  24. 24.
    Beems T, Grotenhuis JA (2001) Subependymal giant-cell astrocytoma in tuberous sclerosis: endoscopic images and the implications for therapy. Minim Invasive Neurosurg 44:58–60CrossRefPubMedGoogle Scholar
  25. 25.
    Hyman MH, Whittemore VH (2000) National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 57:662–665CrossRefPubMedGoogle Scholar
  26. 26.
    Palmieri A, De Vecchio E, Pirolo R, Gardeur D, Ambrosio A (1982) The current potential of neuroradiology in the diagnosis of tuberous sclerosis. Ital J Neurol Sci 3:229–233CrossRefPubMedGoogle Scholar
  27. 27.
    Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345–56CrossRefPubMedGoogle Scholar
  28. 28.
    Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosom Cancer 42:213–27CrossRefPubMedGoogle Scholar
  29. 29.
    Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498CrossRefPubMedGoogle Scholar
  30. 30.
    Koenig MK, Butler IJ, Northrup H (2008) Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 23:1238–1239CrossRefPubMedGoogle Scholar
  31. 31.
    Muncy J, Butler IJ, Koenig MK (2009) Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol 24:477CrossRefPubMedGoogle Scholar
  32. 32.
    Tarasewicz A, Debska-Slizień A, Konopa J, Zdrojewski Z, Rutkowski B (2009) Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc 41:3677–3682CrossRefPubMedGoogle Scholar
  33. 33.
    Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U (2010) Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer 54:476–479CrossRefPubMedGoogle Scholar
  34. 34.
    Wong M (2010) Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 51:27–36CrossRefPubMedGoogle Scholar
  35. 35.
    Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19:1773–1778CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Tao Jiang
    • 1
    • 2
  • Ge Jia
    • 1
  • ZhenYu Ma
    • 1
  • ShiQi Luo
    • 1
  • YuQi Zhang
    • 1
    • 2
  1. 1.Department of Neurosurgery, Beijing Tiantan HospitalCapital Medical UniversityBeijingPeople’s Republic of China
  2. 2.Pediatric Neurosurgical Research Lab, Beijing Neurosurgical InstituteCapital Medical UniversityBeijingChina

Personalised recommendations